公司表示，本次公布的研究成果，是全球范围内首次披露的一项CLDN18.2靶向抗体联合化疗及PD-1抑制剂三联治疗一线胃癌的临床研究成果，为探索全新的胃癌一线标准治疗提供了循证医学支持。Osecon (002755.SZ) announced that AskGene Limited, a subsidiary of the company...
Zhitong Finance App News, Osecon (002755.SZ) announced that the company's subsidiary AskGene Limited announced the latest research results in first-line treatment of advanced gastric cancer in the form of a poster at the American Society of Clinical Oncology Gastrointestinal Oncology Symposium (“2024 ASCO GI”) on January 18, 2024.
According to reports, the study concluded that ASKB589 (CLDN18.2 monoclonal antibody) combined with CAPOX (oxaliplatin and capecitabine) and PD-1 inhibitors were first-line treatment of locally advanced, recurrent, or metastatic gastric and esophagastric adenocarcinoma patients. While showing deep tumor remission and sustained anti-tumor activity, ASKB589 had good safety and tolerability. The phased results of this study support NMPA's approval of the critical phase III clinical study of ASKB589 in combination with chemotherapy and PD-1 inhibitors.
The company said that the research results announced this time are the first clinical research results disclosed worldwide in the triad treatment of first-line gastric cancer with CLDN18.2 targeted antibodies combined with chemotherapy and PD-1 inhibitors, providing evidence-based medical support for exploring a new first-line standard treatment for gastric cancer.
